Nektar Therapeutics Overview
- Year Founded
-
1990
- Status
-
Public
- Employees
-
63
- Stock Symbol
-
NKTR
- Investments
-
3
- Share Price
-
$37.27
- (As of Friday Closing)
Nektar Therapeutics General Information
Description
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Contact Information
Website
www.nektar.comCorporate Office
- 455 Mission Bay Boulevard South
- San Francisco, CA 94158
- United States
Corporate Office
- 455 Mission Bay Boulevard South
- San Francisco, CA 94158
- United States
Nektar Therapeutics Stock Performance
As of 13-Nov-2026, Nektar Therapeutics’s stock price is $37.27. Its current market cap is $1.28B with 34.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $37.27 | $37.25 | $33.40 - $109.00 | $1.28B | 34.2M | 1.1M | -$6.38 |
Nektar Therapeutics Financials Summary
As of 30-Sep-2026, Nektar Therapeutics has a trailing 12-month revenue of $52.2M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,461,403 | 681,749 | 35,313 | (143,585) |
| Revenue | 52,185 | 55,232 | 98,427 | 90,122 |
| EBITDA | (166,735) | (138,715) | (101,197) | (262,116) |
| Net Income | (177,256) | (164,076) | (118,961) | (276,056) |
| Total Assets | 1,037,251 | 280,406 | 303,850 | 398,033 |
| Total Debt | 73,881 | 85,751 | 102,564 | 117,776 |
Nektar Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nektar Therapeutics Comparisons
Industry
Financing
Details
Nektar Therapeutics Competitors (97)
One of Nektar Therapeutics’s 97 competitors is Seagen, a Formerly VC-backed company based in Bothell, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seagen | Formerly VC-backed | Bothell, WA | ||||
| Incyte | Formerly VC-backed | Wilmington, DE | ||||
| Exelixis | Formerly VC-backed | Alameda, CA | ||||
| Coherus Oncology | Formerly VC-backed | Redwood City, CA | ||||
| Agenus | Formerly VC-backed | Lexington, MA |
Nektar Therapeutics Patents
Nektar Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026064439-A1 | Polymer engineered forms of colony stimulating factor-1 | Pending | 18-Sep-2024 | ||
| WO-2025250701-A1 | Anti-tumor necrosis factor receptor 2 (tnfr2) antibodies and methods of use | Pending | 28-May-2024 | ||
| AU-2022414070-A1 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | Pending | 14-Dec-2021 | ||
| CA-3239501-A1 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | Pending | 14-Dec-2021 | ||
| EP-4447995-A1 | Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions | Pending | 14-Dec-2021 | A61K47/60 |
Nektar Therapeutics Signals
Nektar Therapeutics Investments & Acquisitions (3)
Nektar Therapeutics’s most recent deal was a Early Stage VC with Pearl Therapeutics for . The deal was made on 01-Jul-2008.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pearl Therapeutics | 01-Jul-2008 | Early Stage VC | Drug Discovery | ||
| Aerogen | 20-Oct-2005 | Merger/Acquisition | Drug Delivery | ||
| Shearwater | 01-Jun-2001 | Merger/Acquisition | Specialty Chemicals |
Nektar Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
43.08 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Nektar Therapeutics Exits (1)
Nektar Therapeutics’s most recent exit was on 01-Jul-2008 from Pearl Therapeutics. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Pearl Therapeutics | 01-Jul-2008 | Completed |
|
Nektar Therapeutics FAQs
-
When was Nektar Therapeutics founded?
Nektar Therapeutics was founded in 1990.
-
Where is Nektar Therapeutics headquartered?
Nektar Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Nektar Therapeutics?
Nektar Therapeutics has 63 total employees.
-
What industry is Nektar Therapeutics in?
Nektar Therapeutics’s primary industry is Drug Discovery.
-
Is Nektar Therapeutics a private or public company?
Nektar Therapeutics is a Public company.
-
What is Nektar Therapeutics’s stock symbol?
The ticker symbol for Nektar Therapeutics is NKTR.
-
What is the current stock price of Nektar Therapeutics?
As of 13-Nov-2026 the stock price of Nektar Therapeutics is $37.27.
-
What is the current market cap of Nektar Therapeutics?
The current market capitalization of Nektar Therapeutics is $1.28B.
-
What is Nektar Therapeutics’s current revenue?
The trailing twelve month revenue for Nektar Therapeutics is $52.2M.
-
Who are Nektar Therapeutics’s competitors?
Seagen, Incyte, Exelixis, Coherus Oncology, and Agenus are some of the 97 competitors of Nektar Therapeutics.
-
What is Nektar Therapeutics’s annual earnings per share (EPS)?
Nektar Therapeutics’s EPS for 12 months was -$6.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process